Overview

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female subjects. Each subject will be randomized to receive either a single dose of BPN14770 or placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Tetra Discovery Partners